Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice

Gordon H. Guyatt, Carol Estwing Ferrans, Michele Y. Halyard, Dennis A. Revicki, Tara L. Symonds, Claudette G. Varricchio, Anna Kotzeva, Jose M. Valderas, Jordi L. Alonso

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Quality-of-life (QOL) instruments used in clinical research can provide important evidence to inform decisions about alternative treatments. This is particularly true when patients, such as those with cancer who are contemplating toxic chemotherapy, face tradeoffs between quantity of life and QOL or when the primary goal of therapy is to improve how patients feel. Surrogate measures (cardiac function, exercise capacity, bone density, tumor size) are inadequate substitutes for direct measurement of QOL. Quality-of-life measures will be most valuable when they comprehensively measure aspects of QOL that are both important to patients and likely to be influenced by therapy, when the QOL measurement instruments are valid (measuring what is intended) and responsive (able to detect all important changes, even if small), and when the results are readily interpretable (determining whether treatment-related changes are trivial, small but important, or large). Researchers are finding new, imaginative ways to help clinicians understand the magnitude of treatment impact on QOL. Additionally, QOL measures may be useful in clinical practice. Recent results from well-designed randomized controlled trials suggest that information on patient QOL provided to clinicians might, in some circumstances, result in benefits for these patients. Further investigation is warranted to confirm these observations and to define the particular combination of methods and settings most likely to yield important benefits.

Original languageEnglish (US)
Pages (from-to)1229-1239
Number of pages11
JournalMayo Clinic Proceedings
Volume82
Issue number10
DOIs
StatePublished - 2007

Fingerprint

Quality of Life
Research
Therapeutics
Poisons
Bone Density
Neoplasms
Randomized Controlled Trials
Research Personnel
Exercise
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Guyatt, G. H., Ferrans, C. E., Halyard, M. Y., Revicki, D. A., Symonds, T. L., Varricchio, C. G., ... Alonso, J. L. (2007). Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clinic Proceedings, 82(10), 1229-1239. https://doi.org/10.4065/82.10.1229

Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. / Guyatt, Gordon H.; Ferrans, Carol Estwing; Halyard, Michele Y.; Revicki, Dennis A.; Symonds, Tara L.; Varricchio, Claudette G.; Kotzeva, Anna; Valderas, Jose M.; Alonso, Jordi L.

In: Mayo Clinic Proceedings, Vol. 82, No. 10, 2007, p. 1229-1239.

Research output: Contribution to journalArticle

Guyatt, GH, Ferrans, CE, Halyard, MY, Revicki, DA, Symonds, TL, Varricchio, CG, Kotzeva, A, Valderas, JM & Alonso, JL 2007, 'Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice', Mayo Clinic Proceedings, vol. 82, no. 10, pp. 1229-1239. https://doi.org/10.4065/82.10.1229
Guyatt, Gordon H. ; Ferrans, Carol Estwing ; Halyard, Michele Y. ; Revicki, Dennis A. ; Symonds, Tara L. ; Varricchio, Claudette G. ; Kotzeva, Anna ; Valderas, Jose M. ; Alonso, Jordi L. / Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 10. pp. 1229-1239.
@article{77080a8393d7421093fe220928240f51,
title = "Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice",
abstract = "Quality-of-life (QOL) instruments used in clinical research can provide important evidence to inform decisions about alternative treatments. This is particularly true when patients, such as those with cancer who are contemplating toxic chemotherapy, face tradeoffs between quantity of life and QOL or when the primary goal of therapy is to improve how patients feel. Surrogate measures (cardiac function, exercise capacity, bone density, tumor size) are inadequate substitutes for direct measurement of QOL. Quality-of-life measures will be most valuable when they comprehensively measure aspects of QOL that are both important to patients and likely to be influenced by therapy, when the QOL measurement instruments are valid (measuring what is intended) and responsive (able to detect all important changes, even if small), and when the results are readily interpretable (determining whether treatment-related changes are trivial, small but important, or large). Researchers are finding new, imaginative ways to help clinicians understand the magnitude of treatment impact on QOL. Additionally, QOL measures may be useful in clinical practice. Recent results from well-designed randomized controlled trials suggest that information on patient QOL provided to clinicians might, in some circumstances, result in benefits for these patients. Further investigation is warranted to confirm these observations and to define the particular combination of methods and settings most likely to yield important benefits.",
author = "Guyatt, {Gordon H.} and Ferrans, {Carol Estwing} and Halyard, {Michele Y.} and Revicki, {Dennis A.} and Symonds, {Tara L.} and Varricchio, {Claudette G.} and Anna Kotzeva and Valderas, {Jose M.} and Alonso, {Jordi L.}",
year = "2007",
doi = "10.4065/82.10.1229",
language = "English (US)",
volume = "82",
pages = "1229--1239",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice

AU - Guyatt, Gordon H.

AU - Ferrans, Carol Estwing

AU - Halyard, Michele Y.

AU - Revicki, Dennis A.

AU - Symonds, Tara L.

AU - Varricchio, Claudette G.

AU - Kotzeva, Anna

AU - Valderas, Jose M.

AU - Alonso, Jordi L.

PY - 2007

Y1 - 2007

N2 - Quality-of-life (QOL) instruments used in clinical research can provide important evidence to inform decisions about alternative treatments. This is particularly true when patients, such as those with cancer who are contemplating toxic chemotherapy, face tradeoffs between quantity of life and QOL or when the primary goal of therapy is to improve how patients feel. Surrogate measures (cardiac function, exercise capacity, bone density, tumor size) are inadequate substitutes for direct measurement of QOL. Quality-of-life measures will be most valuable when they comprehensively measure aspects of QOL that are both important to patients and likely to be influenced by therapy, when the QOL measurement instruments are valid (measuring what is intended) and responsive (able to detect all important changes, even if small), and when the results are readily interpretable (determining whether treatment-related changes are trivial, small but important, or large). Researchers are finding new, imaginative ways to help clinicians understand the magnitude of treatment impact on QOL. Additionally, QOL measures may be useful in clinical practice. Recent results from well-designed randomized controlled trials suggest that information on patient QOL provided to clinicians might, in some circumstances, result in benefits for these patients. Further investigation is warranted to confirm these observations and to define the particular combination of methods and settings most likely to yield important benefits.

AB - Quality-of-life (QOL) instruments used in clinical research can provide important evidence to inform decisions about alternative treatments. This is particularly true when patients, such as those with cancer who are contemplating toxic chemotherapy, face tradeoffs between quantity of life and QOL or when the primary goal of therapy is to improve how patients feel. Surrogate measures (cardiac function, exercise capacity, bone density, tumor size) are inadequate substitutes for direct measurement of QOL. Quality-of-life measures will be most valuable when they comprehensively measure aspects of QOL that are both important to patients and likely to be influenced by therapy, when the QOL measurement instruments are valid (measuring what is intended) and responsive (able to detect all important changes, even if small), and when the results are readily interpretable (determining whether treatment-related changes are trivial, small but important, or large). Researchers are finding new, imaginative ways to help clinicians understand the magnitude of treatment impact on QOL. Additionally, QOL measures may be useful in clinical practice. Recent results from well-designed randomized controlled trials suggest that information on patient QOL provided to clinicians might, in some circumstances, result in benefits for these patients. Further investigation is warranted to confirm these observations and to define the particular combination of methods and settings most likely to yield important benefits.

UR - http://www.scopus.com/inward/record.url?scp=34848924964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848924964&partnerID=8YFLogxK

U2 - 10.4065/82.10.1229

DO - 10.4065/82.10.1229

M3 - Article

C2 - 17908529

AN - SCOPUS:34848924964

VL - 82

SP - 1229

EP - 1239

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -